Clovis Oncology, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenues:
Product revenue, net
Product revenue
Product
Total product revenue

Operating expenses:
Cost of sales - product
Cost of sales - intangible asset amortization
Cost of sales
Product
Intangible asset amortization
Research and development
Selling, general and administrative
Impairment of intangible asset
Change in fair value of contingent purchase consideration
Acquired in-process research and development
Other operating expenses
Total expenses

Operating loss
Other income (expense):
Interest expense
Foreign currency loss
Loss on convertible senior notes conversion
(Loss) gain on extinguishment of debt
Legal settlement loss
Other income
Other income (expense), net
Loss before income taxes
Income tax (expense) benefit
Net loss
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax
Net unrealized loss on available-for-sale securities, net of tax
Other comprehensive income (loss):
Comprehensive loss
Loss per basic and diluted common share:
Basic net loss per common share
Diluted net loss per common share
Basic weighted average common shares outstanding
Diluted weighted average common shares outstanding

Comments